ReviewDrugs2015
Secukinumab: first global approval.
Review in Drugs, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 115 citations in OpenAlex.
- A Randomized, Double-Blind, Parallel-Group Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of CMAB015, a Candidate Secukinumab Biosimilar, with Its Reference Product CosentyxDrug design, development and therapy · 2024Trial
- Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial.The British journal of dermatology · 2021Trial
- Glycan-based biological degraders targeting the cytokine immune axis.Communications biology · 2026Article
- The Pathophysiological Significance of Dual Inhibition of IL-17A and IL-17F in Psoriatic Arthritis and Axial Spondyloarthritis.Mediterranean journal of rheumatology · 2026Review
- TScience advances · 2025Article
- Safety and effectiveness of secukinumab in Japanese patients with generalized pustular psoriasis: A post-marketing surveillance.The Journal of dermatology · 2025Observational
- Interaction between Th17 and central nervous system in multiple sclerosis.Brain, behavior, & immunity - health · 2025Review
- Risankizumab Versus Secukinumab: A Real-World Efficacy and Cost per Responder Comparison in Patients With Psoriasis in Italy.Dermatology practical & conceptual · 2025Article
- Comprehensive assessment of 5 interleukin inhibitors for the treatment of psoriasis: scientific guidance based on drug selection recommendations for Chinese medical institutions.Journal of pharmaceutical policy and practice · 2025Article
- The Nuclear NF-κB Regulator IκBζ: Updates on Its Molecular Functions and Pathophysiological Roles.Cells · 2024Review
- Effectiveness of secukinumab in patients with psoriasis and psoriatic arthritis in a Saudi real-world setting.Advances in rheumatology (London, England) · 2024Article
- Risk of candidiasis associated with interleukin-17 inhibitors: Implications and management.Mycology · 2024Review
- Investigating immune profile by CyTOF in individuals with long-standing type 1 diabetes.Scientific reports · 2023Article
- Identification immune response genes in psoriasis after treatment with secukinumab.BMC medical genomics · 2023Article
- Global trends and research status in ankylosing spondylitis clinical trials: a bibliometric analysis of the last 20 years.Frontiers in immunology · 2023Article
- Real-world experience of secukinumab in moderate to severe psoriasis patients in Thailand: Characteristics, effectiveness, and safety.Dermatologic therapy · 2022Article
- Gradually increasing the dosing interval of Secukinumab for moderate to severe plaque psoriasis: A single-center, uncontrolled, prospective study in 36 weeks.Dermatologic therapy · 2022Article
- Two Epitope Regions Revealed in the Complex of IL-17A and Anti-IL-17A VInternational journal of molecular sciences · 2022Article
- The Role of Interleukin-17 in Juvenile Idiopathic Arthritis: From Pathogenesis to Treatment.Medicina (Kaunas, Lithuania) · 2022Review
- Divergent functions of IL-17-family cytokines in DSS colitis: Insights from a naturally-occurring human mutation in IL-17F.Cytokine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Secukinumab (Cosentyx™) is a fully human monoclonal antibody against interleukin-17A, formulated for intravenous and subcutaneous administration. It received its first global approval in Japan on 26 December 2014 for the treatment of psoriasis and psoriatic arthritis in adults who are not adequately responding to systemic therapies (except for biologic agents). In the USA and the EU, secukinumab was approved in early 2015 for the treatment of patients with moderate-to-severe plaque psoriasis. Secukinumab is also being investigated in patients with ankylosing spondylitis and rheumatoid arthritis. This article summarizes the milestones in the development of secukinumab leading to its first approval for the treatment of adult patients with psoriasis and psoriatic arthritis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.